Sign inCreate account

Report workspace tools

NCT04743115UNKNOWNanonymous

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Sponsor

Source record

Shanghai Bensen Pharmaceutical Co., Ltd.

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Indication / condition

AI-normalized

Acute Myeloid Leukemia, Myelodysplastic Syndrome

Intervention

Source record

BS HH 002.SA

Source & freshness

Source record

NCT ID

NCT04743115

Original source

ClinicalTrials.gov

Source last updated

Feb 08, 2021

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04743115

Title

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Sponsor

Shanghai Bensen Pharmaceutical Co., Ltd.

Status

UNKNOWN

Phase

Phase 1

Condition raw

Acute Myeloid Leukemia, Myelodysplastic Syndrome

Condition normalized

Acute Myeloid Leukemia, Myelodysplastic Syndrome

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Target normalized

Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Interventions

BS HH 002.SA

Public preview

Source record

BS HH 002.SA is being developed by Shanghai Bensen Pharmaceutical Co., Ltd. for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS). The target patient population is significant due to the limited treatment options available for these conditions, suggesting a potentially lucrative market. The study's design includes a dose escalation and cohort expansion, indicating a strategic approach to establishing safety and efficacy. The competitive landscape includes other emerging therapies for AML and MDS, necessitating diligent monitoring of similar clinical trials and market entrants. The trial's current status is 'Not Yet Recruiting,' which may impact timelines for market entry and revenue generation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04743115

Status

UNKNOWN

Phase

Phase 1

Sponsor

Shanghai Bensen Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

BS HH 002.SA is being developed by Shanghai Bensen Pharmaceutical Co., Ltd. for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS). The target patient population is significant due to the limited treatment options available for these conditions, suggesting a potentially lucrative market. The study's design includes a dose escalation and cohort expansion, indicating a strategic approach to establishing safety and efficacy. The competitive landscape includes other emerging therapies for AML and MDS, necessitating diligent monitoring of similar clinical trials and market entrants. The trial's current status is 'Not Yet Recruiting,' which may impact timelines for market entry and revenue generation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 08, 2021
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04743115

Indication

Acute Myeloid Leukemia, Myelodysplastic Syndrome

Modality

small molecule

Target

Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Intervention

BS HH 002.SA

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.